Sol-gel
SLGL

Sol-gel (SLGL) analyst forecast and price target

Analyst forecast

Buy

Consensus of 4 analyst ratings

Buy
4
Hold
0
Sell
0

Recent analyst ratings

FirmActionRatingPrice targetDate
Cantor FitzgeraldInitiated CoverageOverweight—Oct 14, 2026
HC Wainwright & Co.MaintainedBuy$110.00Jul 20, 2026
MizuhoInitiated CoverageOutperform$285.00Jun 24, 2026
HC Wainwright & Co.MaintainedBuy$110.00 from $50.00Jan 20, 2026
HC Wainwright & Co.MaintainedBuy$50.00Dec 22, 2025
HC Wainwright & Co.MaintainedBuy$50.00 from $6.00Oct 27, 2025
Raymond JamesDowngradedStrong Buy → Outperform$4.00 from $6.00Aug 19, 2024
HC Wainwright & Co.MaintainedBuy$6.00May 22, 2024
HC Wainwright & Co.MaintainedBuy$6.00 from $9.00May 20, 2024
HC Wainwright & Co.MaintainedBuy$9.00 from $12.00Nov 13, 2023
HC Wainwright & Co.MaintainedBuy$12.00 from $19.00Aug 14, 2023
Raymond JamesMaintainedStrong Buy$7.00 from $9.00Aug 11, 2023
HC Wainwright & Co.MaintainedBuy$19.00Jul 24, 2023
Raymond JamesMaintainedStrong Buy$9.00 from $10.00Jul 19, 2023
HC Wainwright & Co.MaintainedBuy$19.00Jun 5, 2023

Frequently asked questions

  • Is SLGL a buy, sell, or hold?

    Analysts covering Sol-gel currently average a Buy rating: 4 buy, 0 hold and 0 sell, from 4 analysts. Ratings reflect analyst opinion, not investment advice.

  • What is the latest analyst rating on SLGL?

    On Oct 14, 2026, Cantor Fitzgerald initiated coverage of Sol-gel at Overweight.

Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.